Search company, investor...


Biz Plan Competition | Alive

Total Raised


Last Raised

$10K | 15 yrs ago

About Knoesis

Knoesis seeks to develop bio-analytical hardware and reagents enabling cost-effective clinical diagnostics. The vision of the company is to allow everyone affordable access to rapid and specific diagnostic healthcare knowledge. Knoesis' first application is an immunosensor for the detection of latent tuberculosis infection.

Headquarters Location

Raleigh, North Carolina, 27601,

United States



Knoesis Frequently Asked Questions (FAQ)

  • Where is Knoesis's headquarters?

    Knoesis's headquarters is located at Raleigh.

  • What is Knoesis's latest funding round?

    Knoesis's latest funding round is Biz Plan Competition.

  • How much did Knoesis raise?

    Knoesis raised a total of $10K.

  • Who are the investors of Knoesis?

    Investors of Knoesis include Duke Start-up Challenge.

  • Who are Knoesis's competitors?

    Competitors of Knoesis include Ikonisys, Binx Health, Capso Vision, BionX Medical Technologies, Softcup and 7 more.


Compare Knoesis to Competitors

Biointraface Logo

Biointraface is developing a technology to thwart infection relating to medical-device use.

Binx Health Logo
Binx Health

Binx Health is a healthcare company focused on point-of-care molecular diagnostics. The company offers diagnostic solutions that enable healthcare providers to deliver timely, high-quality care, including a testing platform for the diagnosis and treatment of chlamydia and gonorrhea infections. Binx Health primarily serves the healthcare industry. Binx Health was formerly known as Atlas Genetics. It was founded in 2005 and is based in Cambridge, Massachusetts.


Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.


Lifepoint is a medical technology company developing rapid and cost effective, non-invasive, on-site diagnostic products. The Company has developed and will continue to develop patented, proprietary technologies utilizing saliva as a test specimen to provide blood equivalent diagnostic results without the need for blood or urine.


Diamics, Inc. is a medical device and diagnostics company. The company is developing, manufacturing, and marketing cost effective cancer diagnostic systems that will increase long-term cancer survival rates through early detection.

NIR Diagnostics

NIR Diagnostics is developing a diagnostic device to quantitatively assess the progress of the wound healing process. Per the company, the device has the potential to be a more accurate, more rapid, and less expensive method of wound assessment compared to those currently on the market.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.